Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer

NCT06542549 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER_GOV

Sponsor class

Conditions

Advanced Ovarian Cancer
AK104(PD-1/CTLA-4 Bispecial Antibody)
Chemotherapy
Efficacy
Safety

Interventions

DRUG: AK104

Sponsor

Anhui Provincial Hospital